Posted by Michael Wonder on 09 Mar 2021
Sesen Bio submits marketing authorisation application to the European Medicines Agency for Vicineum
8 March 2021 - Potential approval in Europe anticipated in early 2022.
Sesen Bio announced that on 5 March 2021 the Company submitted its marketing authorisation application to the EMA for Vicineum for the treatment of high risk, BCG unresponsive non-muscle invasive bladder cancer under the EMA’s centralised procedure.
